Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More
Xconomy
MARCH 30, 2018
The number of companies filing to go public in the U.S. Life science companies accounted for nearly one third of the quarter’s IPOs. The strength of the IPO market is notable because the first quarter is typically the slowest time of the year for companies to go public, EY told Xconomy.
52 
Let's personalize your content